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Capsular polysaccharides (CP) of serotypes 5 (CP5) and 8 (CP8) are major Staphylococcus aureus virulence
factors. Previous studies have shown that salicylic acid (SAL), the main aspirin metabolite, affects the expression
of certain bacterial virulence factors. In the present study, we found that S. aureus strain Reynolds (CP5) cultured
with SAL was internalized by MAC-T cells in larger numbers than strain Reynolds organisms not exposed to SAL.
Furthermore, the internalization of the isogenic nonencapsulated Reynolds strain into MAC-T cells was not
significantly affected by preexposure to SAL. Pretreatment of S. aureus strain Newman with SAL also enhanced
internalization into MAC-T cells compared with that of untreated control strains. Using strain Newman organisms,
we evaluated the activity of the major cap5 promoter, which was significantly decreased upon preexposure to SAL.
Diminished transcription of mgrA and upregulation of the saeRS transcript, both global regulators of CP expression,
were found in S. aureus cultured in the presence of SAL, as ascertained by real-time PCR analysis. In addition, CP5
production by S. aureus Newman was also decreased by treatment with SAL. Collectively, our data demonstrate that
exposure of encapsulated S. aureus strains to low concentrations of SAL reduced CP production, thus unmasking
surface adhesins and leading to an increased capacity of staphylococci to invade epithelial cells. The high capacity
of internalization of the encapsulated S. aureus strains induced by SAL pretreatment may contribute to the
persistence of bacteria in certain hosts.
regularly taken by hundreds of millions of individuals worldwide due to its known analgesic and cardiovascular protective
activities. The main aspirin biometabolite, salicylic acid (SAL),
affects the expression of bacterial virulence factors (45). A
study performed using a rabbit model of endocarditis demonstrated that SAL causes a reduction in S. aureus virulence (23,
24). Biofilm formation and attachment of S. aureus strain 8325
to the Arabidopsis thaliana root surface were disrupted by a low
concentration of SAL (48). It has also been shown that the
effects of SAL on S. aureus include activation of the sigB
operon via both rsbU-dependent and -independent mechanisms (24, 42). Moreover, growth of S. aureus in the presence
of SAL reduced bacterial susceptibility to multiple antimicrobials (16, 44, 46, 47).
S. aureus can adhere to and invade nonprofessional phagocytic cells (9, 12, 54). The relevance of this finding is that
intracellular S. aureus may be a source of persistent or recurrent infection (60). Results from our laboratory demonstrated
that the production of CP5 (or CP8) reduced the internalization of S. aureus into epithelial cells (4, 57). Growth of Klebsiella pneumoniae, a capsule-containing microorganism, in the
presence of SAL also resulted in reduced synthesis of CP (6, 7).
In this study, we evaluated whether SAL negatively affects CP5
expression in S. aureus, thus enhancing the capacity of S. aureus to invade epithelial cells.

Staphylococcus aureus is an opportunistic pathogen that causes
both community-acquired and life-threatening nosocomial infections (35). Although S. aureus can colonize mucosal surfaces of
healthy humans, it is also a major cause of skin and soft tissue
infections and has the invasive potential to cause severe infections, including osteomyelitis, endocarditis, and bacteremia with
metastatic complications (35). The pathogenicity of S. aureus depends upon successful adaptation of the microorganism to the
host and the coordinated expression of virulence factors. S. aureus
is usually surrounded by a thin capsule, and capsular polysaccharides (CP) of serotypes 5 (CP5) and 8 (CP8) are the most prevalent ones in clinical isolates from humans (40). S. aureus CP5 and
CP8 are antiphagocytic and positively contribute to the virulence
of this pathogen (27, 40). Production of CP5 (or CP8) may be
deeply modified by different global regulators (agr, arlRS, saeRS,
and sarA) and transcriptional factors (mgrA, B) (30, 31, 34, 55,
59). A recent report has shown that the sbcDC locus mediates
repression of CP5 production as a part of the SOS response in S.
aureus (5). Furthermore, the expression of CP5 (7) is highly sensitive to diverse environmental signals, such as iron concentration,
specific nutrients, CO2 concentration, or subinhibitory concentrations of ciprofloxacin and mitomycin C (5, 17, 26, 40).
Aspirin is a nonsteroidal anti-inflammatory agent that is
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MATERIALS AND METHODS
Bacterial isolates and growth conditions. Bacterial strains and plasmids used
in this study are listed in Table 1. Bacteria were stored in Trypticase soy broth
(TSB) (Difco, Detroit, MI) with 20% glycerol at ⫺20°C until use. S. aureus was
routinely cultured at 37°C and 200 rpm for 18 h in Casamino Acids-yeast extract-
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TABLE 1. Staphylococcus aureus strains and plasmids used in this study

Strain or plasmid

S. aureus strains
Newman
RN6390
Reynolds (CP5)
Reynolds (CP⫺)
ALC2547
ALC4483
ALC1842
ALC5163
ALC6141
ALC3257
Plasmids
pALC1484
pALC1766
pALC4991
pALC2566

Description

Reference

Clinical isolate (ATCC 25904); CP5 producer
Laboratory strain related to 8325-4
Capsular polysaccharide serotype 5 strain Reynolds
Reynolds (CP5) isogenic mutant that does not express CP5
mgrA mutant of Newman (⌬mgrA::ermC)
Newman sae single-deletion mutant
Strain Newman with pALC1766
Strain Newman with pALC4991
Strain Newman with pALC2566
Strain Newman with pALC1484

8
22
62
62
20
28
59
28
19
33

Derivative of pSK236 containing the promoterless gfpuvr gene preceded by an S. aureus ribosome
binding site
Derivative of pALC1484 containing the main cap5 promoter driving the expression of the gfpuvr gene
Derivative of pALC1484 containing the sae P3 promoter driving the expression of the gfpuvr gene
Derivative of pALC1484 containing the mgrA promoter driving the expression of the gfpuvr gene

33

glycerophosphate (CYGP) broth without glucose (CYGPw) (38). When necessary, SAL was added to the culture medium at 50 g/ml (0.36 mM). For cell
invasion experiments, bacterial cells were collected by centrifugation, washed
with sterile saline solution, and suspended in invasion medium (see below) to a
density of ca. 107 CFU/ml.
Antigenic extracts. Bacterial extracts from wild-type Newman and mgrA and
saeRS isogenic mutant strains (Table 1) were prepared as previously described
(56). Briefly, S. aureus was cultured for 24 h at 37°C on Columbia agar (Difco)
supplemented with 2% NaCl, to enhance CP production, plus 0.36 or 2 mM SAL.
Controls were cultured in the same medium with no SAL added. The colonies
from one plate were harvested in 1 ml of 10 mM phosphate-buffered saline (PBS)
(0.15 M NaCl, pH 7.2), and the cell suspensions were autoclaved for 1 h at 121°C.
Bacteria were pelleted by centrifugation at 10,000 ⫻ g, and the supernatants
containing the cell extracts were passed through 0.45-m filters and stored at
⫺20°C. Bacterial extracts from isogenic Reynolds (CP5) and Reynolds (CP⫺)
(nonencapsulated) reference strains of S. aureus were used as positive and
negative controls, respectively.
CP expression by immunoprecipitation. CP5 expression in S. aureus Newman
was determined by immunoprecipitation in the presence of 0.36 or 2 mM SAL as
previously described (21). Briefly, a 1% agarose gel was prepared on a glass slide,
and wells were punched in a circular fashion around a central hole. Absorbed
type 5 antiserum (25) was added to the central well, and serial dilutions of
bacterial extracts [including known serotype 5 Reynolds (CP5) and nonencapsulated Reynolds (CP⫺) extracts as controls] were applied to the outer wells.
Immunodiffusion was conducted in a moist chamber at room temperature. After
24 h, the precipitin lines were examined by staining with Coomassie brilliant blue.
Cell culture. The established bovine mammary epithelial cell line MAC-T (18)
was generously provided by Nexia Biotechnologies (Quebec, Canada). MAC-T
cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco BRL,
Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum
(Gibco BRL), insulin (5 g/ml), hydrocortisone (5 g/ml), penicillin (100 U/ml),
and streptomycin sulfate (100 g/ml) (Sigma Chemical Co., St. Louis, MO).
Prior to each experiment, MAC-T cells were seeded at 1.5 ⫻ 105 cells/well in
24-well tissue culture plates and grown for 24 h at 37°C with 5% CO2.
Internalization assays. Internalization assays were performed as described
previously (4). Briefly, confluent MAC-T cell monolayers (approximately 2.5 ⫻
105 cells/well) were inoculated with S. aureus suspended in fresh growth medium
without antibiotics (invasion medium) to a multiplicity of infection (MOI) of 40.
Plates were subjected to centrifugation at 1,000 ⫻ g for 20 min to deposit bacteria
on the monolayer surface and to synchronize the bacterial internalization into
cells. After incubation for 1 h at 37°C under 5% CO2, the wells were washed with
PBS, and then 1 ml of invasion medium supplemented with 25 g of lysostaphin
(Sigma) was added to each well to kill extracellular bacteria. Incubation of
cocultures with lysostaphin proceeded for an additional 2 h at 37°C with 5% CO2.
Supernatants were then collected and plated on Trypticase soy agar (TSA) to
verify 100% bacterial killing by lysostaphin. The monolayer was washed with
sterile PBS, treated for 5 min at 37°C with 100 l of 0.25% trypsin–0.1% EDTA
(Gibco BRL), and lysed by the addition of 900 l of 0.025% Triton X-100 (USB,

59
28
19

Cleveland, OH) in sterile distilled water to release intracellular staphylococci.
The CFU number was determined by quantitative plating on TSA. MAC-T cell
viability was evaluated by trypan blue exclusion.
Transcriptional fusion studies. After overnight culture, S. aureus strains harboring different recombinant plasmids (Table 1) were diluted 1:100 and grown
with or without 50 g/ml SAL at 37°C with shaking in CYGPw broth. Aliquots
were transferred hourly to microtiter plates and assessed for cell density (optical
density at 650 nm [OD650]) and fluorescence for 9 h in an FL600 fluorescence
spectrophotometer (BioTek Instruments, Winooski, VT). Promoter activities
were plotted as mean fluorescence/OD650 ratios to minimize variations due to
changes in cell density between experiments, using the average values for triplicate readings.
Real-time PCR. Bacterial RNA was extracted using Trizol (Gibco BRL) and
0.1-mm silica beads in a reciprocating shaker (Biospec, Bartlesville, OK) according to the manufacturer’s instructions. RNA was subjected to DNase treatment,
using a Turbo DNAfree kit (Ambion, Austin, TX) according to the manufacturer’s protocol. cDNA synthesis was performed with a Transcriptor first-strand
cDNA synthesis kit (Roche, Basel, Switzerland), using random hexamer primers.
Quantitative real-time PCR was performed using LightCycler FastStart DNA
Master SYBR green I (Roche) equipment and kits. cDNA was subjected to
real-time PCR using the following primers: cap5K-f, 5⬘-CCA GTG AAT TGT
TTG CAA CG-3⬘; cap5K-r, 5⬘-CAT TTT CCC AAT AAA TGT TGA AAG-3⬘;
mgrA-f, 5⬘-GGG ATG AAT CTC CTG TAA AC-3⬘; mgrA-r, 5⬘-GCT GAA
GCG ACT TTG TCA GA-3⬘; saeRS-f, 5⬘-ATG CTA ATA CCG TGA ATG
TCC A-3⬘; saeRS-r, 5⬘-TGG CCG TTA AAC CAC ATT AAA-3⬘ (3.1-, 2.4-, and
2.0-kb sae transcripts were amplified using these primers); gyrB-f, 5⬘-GGT GCT
GGG CAA ATA CAA GT-3⬘; and gyrB-r, 5⬘-TGG GAT ACC ACG TCC GTT
AT-3⬘. The gyrB gene was used as a calibrator and as an internal control to
normalize data. Cycling conditions were 95°C for 10 min followed by 45 cycles of
95°C for 10 s, 55°C for 10 s, and 72°C for 15 s and 1 cycle of 40°C for 30 s. The
number of copies of each sample transcript was determined with the aid of
LightCycler software. The ⫺⌬⌬CT value represents the difference in threshold
cycle (CT) between the target and control (gyrB) genes treated with SAL minus
the difference in CT between the untreated target and control genes (29).
Statistical analysis. Nonparametric data were analyzed with the Mann-Whitney test, using GraphPad software (version 4.0; GraphPad Prism). P values of
⬍0.05 were considered significant.

RESULTS
Effect of SAL on internalization of encapsulated S. aureus.
Previous studies have reported a reduction in staphylococcal
adherence when bacteria are cultured in the presence of SAL
(10, 36, 43). In the present study, we investigated whether S.
aureus strains Newman and RN6390 treated with SAL exhibited a reduced ability to invade epithelial cells. S. aureus New-
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FIG. 1. Effect of SAL on internalization of S. aureus into MAC-T epithelial cells. Confluent MAC-T cells were tested for staphylococcal
invasion. Each bar represents the “percentage of invasion,” defined as the median of intracellular CFU/ml (n ⫽ 9 to 12) from S. aureus strains
related to the median of intracellular CFU/ml from S. aureus RN6390 or Reynolds (CP⫺) without SAL treatment (100% invasion). The asterisks
represent significant differences between strain Newman treated and not treated with SAL (P ⫽ 0.0001) (A) and between Reynolds (CP5)
organisms treated and not treated with SAL (P ⫽ 0.0089; Mann-Whitney test) (B). Comparison of Reynolds (CP5) treated with SAL and Reynolds
(CP⫺) showed no significant differences.

man organisms express CP5, whereas S. aureus RN6390 cells
do not express CP5 due to a mutation in the essential capE5
gene (61). The SAL concentration (0.36 mM) used in the
experiments did not affect the growth of the S. aureus strains
used in this study (data not shown) and represents the levels
achievable in human serum after ingestion of aspirin in pharmacological (antithrombotic) doses (11, 37). Two hours after
addition of lysostaphin to the infected MAC-T cells, the number of intracellular CFU of S. aureus RN6390 cells pretreated
with SAL did not differ significantly compared with that of cells
without SAL pretreatment (Fig. 1A). Preexposure of S. aureus
Newman to SAL significantly enhanced the internalization of
the bacteria into MAC-T cells compared with that of untreated
bacteria (Fig. 1A). This finding was consistent with previous
results from our laboratory demonstrating that S. aureus
strains with no capsule or reduced capsule formation displayed
an increased ability to invade MAC-T cells compared with
those that express either CP5 or CP8, possibly due to unmasking of surface adhesins beneath the capsule (4, 57). The differences observed in the present study were likely attributed to
the influence of SAL on CP expression. To test this hypothesis,
we performed a similar study with S. aureus Reynolds (CP5)
and the isogenic nonencapsulated Reynolds (CP⫺) derivative
under the conditions described above. As shown in Fig. 1B,
Reynolds (CP5) organisms pretreated with SAL were internalized by the MAC-T cells in significantly higher numbers than
those of Reynolds (CP5) organisms not exposed to SAL. Moreover, the invasiveness of the nonencapsulated derivative of the
Reynolds strain was not significantly affected by preexposure to
SAL (data not shown). Taken together, our results demonstrated
that encapsulated strains of S. aureus pretreated with SAL exhibited an increased capacity for invasion of MAC-T epithelial cells,
probably due to decreased CP expression.
cap expression is diminished by SAL treatment. The effect
of SAL on cap5 promoter activity was ascertained by expression of the gfpuvr reporter gene driven by the major cap5
promoter. As shown in Fig. 2A, SAL induced a significant
decrease in the activity of the strain Newman cap5 promoter.
The promoter activities of saeRS and mgrA, two known regu-

lators involved in down- and upmodulation of CP expression,
respectively, were also measured after SAL exposure. These
assays established that treatment with SAL reduced the mgrA
promoter activity (Fig. 2B). However, the main sae promoter
(28) was not affected by SAL treatment at the time point
studied (Fig. 2B). Furthermore, real-time PCR experiments
were performed to estimate the quantities of cap5K, saeRS,
and mgrA transcripts formed under the effects of SAL. Our

FIG. 2. Effect of SAL on cap5 (A), mgrA (B), and sae P3 (B) promoter activities. Expression of gfp driven by the target promoters was
measured during the growth cycle, and fluorescence values were expressed as green fluorescent protein fluorescence related to the OD650
(F/OD) in order to minimize variations in fluorescence due to varying cell
density. The data represent the arithmetic means ⫾ standard deviations
for triplicate measurements from three or four independent experiments.
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FIG. 3. Real-time PCR analysis of cap, mgrA, and sae transcription.
Changes in gene expression are shown as fold changes [⫺(⌬⌬CT)]
following growth with 50 g/ml of SAL to an OD650 of 1.4. The data
represent the means ⫾ standard deviations for duplicate measurements from three independent experiments.

results showed that the levels of expression of cap5K and mgrA
transcripts decreased in S. aureus organisms treated with SAL.
In contrast, SAL treatment increased the level of saeRS transcript expression (Fig. 3). These results demonstrate that pretreatment of S. aureus Newman organisms with SAL decreased
transcription of cap5 and mgrA, an upregulator of CP expression. Decreased transcription of cap5 and mgrA was accompanied by enhanced expression of saeRS, a downregulator of CP
expression, thus contributing to an overall decrease in CP
expression upon SAL exposure.
SAL reduces phenotypic CP expression. The effect of SAL
on CP production was also evaluated by immunoprecipitation,
using monospecific antiserum to CP5. This method was suitable for semiquantitative estimation of the amount of CP produced using twofold serial dilutions of CP extracts (32). A high
concentration of SAL (2 mM) was used to investigate the effect
on CP expression. The results revealed a dose-dependent decrease of CP5 expression, caused by SAL, in S. aureus Newman
organisms (Fig. 4). The highest CP5 expression level was seen
in the control (bacteria not treated with SAL). These results
showed that CP5 production by the Newman strain organisms
was decreased by treatment with SAL.
DISCUSSION
Previous results from our laboratory demonstrated that nonencapsulated S. aureus strains were internalized more efficiently into MAC-T cells than were their encapsulated (CP5⫹
or CP8⫹) counterparts (4, 57). In the present study, we demonstrated that pretreatment of encapsulated (CP5⫹) S. aureus
strain Newman organisms with SAL increased the ability of the
bacteria to invade MAC-T cells. This observation correlated
with a diminished production of CP5. Our experiments were
conducted in medium without glucose to avoid the repression
of CP production (52). Besides, the concentration of SAL (0.36
mM) used matched the antiplatelet concentration achievable
in human plasma (11, 37). It was recently reported that S.
aureus 8325-4 (nonencapsulated) (61) cultured in the presence
of SAL exhibited reduced adhesion to human umbilical vein
endothelial cells (43). In our studies performed with strain
RN6390 (an 8325 strain derivative), we were unable to confirm
these experimental results. This discrepancy, however, can be
explained by the different cell line used and, perhaps more
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FIG. 4. Immunodiffusion analysis of CP5 extracts. Thirty microliters of monospecific antiserum to serotype 5 was added to the center
well. Thirty-microliter samples of undiluted and twofold serially diluted (indicated inside the well) CP5 extracts of Newman strain organisms, cultured or not with different concentrations of SAL, were
added to the outer wells. Precipitin lines were visualized after staining
with Coomassie brilliant blue. C⫹, positive control [undiluted extract
of S. aureus Reynolds (CP5) strain]; C⫺, negative control [undiluted
extract of S. aureus Reynolds (CP⫺) strain]. Precipitin lines were
visible up to a 1:4 dilution of capsular extracts in the control without
SAL, up to a 1:2 dilution at a 0.36 mM SAL concentration, and at only
a 1:1 dilution at the highest SAL concentration (2 mM).

importantly, the major differences in the experimental design
and bacterial growth conditions utilized.
Internalization of S. aureus into mammalian cells depends
upon fibronectin bridging between fibronectin binding proteins
(FnBPs) and the integrin ␣5␤1 (53). Kupferwasser et al. (24)
described that pretreatment of several S. aureus strains with
SAL (0.36 mM) resulted in low levels of adhesion to cell matrix
proteins, such as fibronectin and fibrinogen. In that study, the
reduction in matrix binding protein expression on the surface
of S. aureus represented composite pooled data derived from
S. aureus laboratory strains RN6390, COL, Newman, and
ISP479C as well as from several clinical (methicillin-resistant
S. aureus [MRSA]) S. aureus isolates. Grundmeier et al. (15)
have shown that both fnbA and fnbB of S. aureus Newman
contain a centrally located point mutation resulting in a stop
codon. This causes a truncation of both FnBPs at the end of
the C domain. Consequently, this led to deficient adherence of
strain Newman compared with that of S. aureus strains with
wild-type FnBPs. Our results also confirmed that strain Newman (7 ⫻ 104 CFU/ml) organisms were internalized into
MAC-T cells at lower rates than those of strain RN6390 (4.9 ⫻
105 CFU/ml) organisms. However, when both strains were
cultured in the presence of SAL, only the internalization capability of strain Newman was affected. Moreover, the increased invasion of MAC-T cells after SAL treatment of Newman organisms may suggest that another factor(s) besides CP
may be affected by SAL, thus improving cellular internalization
(2). We are now conducting experiments to evaluate this hypothesis. The preliminary results of SDS-PAGE analysis of
Newman, AH12 (Newman eap mutant), and complemented
strain AH12pCXEap surface proteins revealed increased Eap
expression after SAL treatment in strain Newman (L. P. Alvarez et al., unpublished data). Thus, the increased invasion
observed after SAL treatment may be due not only to the
diminished expression of CP but also to an increased expression of certain adhesins, such as Eap.
The low CP5 production by S. aureus induced by SAL treatment was also seen at the transcriptional level. Previous studies
showed that expression of the cap operon is mainly driven by
the major promoter located at the beginning of the operon (41,
51). The expression of the major cap5 promoter was thus
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monitored with a cap5 promoter-gfp⫹ reporter gene fusion by
measuring fluorescence emission. Indeed, the activity of the
cap5 promoter was diminished by exposure to SAL. Downregulation of CP5 by SAL was also confirmed by analyzing the
cap5K (CP5-specific region) mRNA, using real-time PCR.
Blickwede et al. (3) observed that mRNA expression of cap5A
was decreased in S. aureus strain Newman after treatment with
subinhibitory concentrations of florfenicol (an antibiotic used
in veterinary medicine), indicating that cap expression can be
affected by different pharmacological agents. In the present
study, when the expression of CP5 was evaluated by immunoprecipitation using monospecific antiserum to CP5, we observed a dose-dependent reduction of CP5 production by S.
aureus Newman after SAL treatment. In a study on Gramnegative bacteria, Domenico et al. (6) observed a decrease of
K. pneumoniae CP production by SAL, in a concentrationdependent manner. In particular, at 0.21 mM SAL, CP was
reduced nearly 60%. In both cases, SAL exerted its effect on
CP production at serum concentrations normally attained after
ingestion of aspirin at doses within the therapeutic range.
Expression of the cap operon and CP expression in S. aureus
are known to be under multiple levels of control and affected
by several environmental stimuli (49). Previous studies have
shown that the global regulators agr, mgrA, arlRS, B, sarA, and
saeRS control CP production at the transcriptional level (30,
31, 34, 55, 59). It should be noted that the results from several
previous reports are contradictory. In this regard, the sae locus
has been shown to repress the cap5 genes (55). In contrast,
Rogasch et al. (50) did not find any influence of SaeRS on the
transcription of the cap operon in S. aureus strain Newman or
COL. On the other hand, the sbcD and sbcC genes were involved in the repression of CP5 production through an arl-mgrdependent pathway at subinhibitory concentrations of ciprofloxacin or mitomycin C (5). As expected, we observed that
after SAL treatment of S. aureus strain Newman, the activity of
the mgrA promoter was diminished. In agreement with this
finding, the level of mgrA transcript, as determined by realtime PCR, was also decreased after SAL exposure. Similarly,
Riordan et al. (49) demonstrated that salicylate induction
downregulated mgrA transcripts. In addition, the mgrA mutant
of the Newman strain did not express CP under any of the
conditions studied here (data not shown). Several studies identified four overlapping transcripts (3.1-, 2.4-, 2.0-, and 0.7-kb
mRNAs) of the sae locus (1, 39, 55). The main sae promoter
(28), located upstream of saeP, is strongly autoregulated and
also repressed by SigB in strains 8325-4, ISP479R, UAMS-1,
and COL (13). This sae promoter appears to be activated by
H2O2 and subinhibitory concentrations of ␣-defensins (13).
Conversely, the main sae promoter did not respond to high salt
concentrations (1). We did not observe any effect on the main
sae promoter’s activity by SAL treatment of S. aureus Newman
strain organisms at the time points studied. However, the level
of sae transcripts (3.1-, 2.4-, and 2.0-kb transcripts included)
increased after SAL exposure. Previous studies showed that
the sae transcripts T3 (3.1 kb), T1 (2.4 kb), and T4 (0.7 kb)
were highly expressed in strain Newman compared with those
in strain 8325-4 (14, 55).
Since the sae system of the Newman strain is not activated by
agr or repressed by sigB (13), we suggest that the diminished
CP5 production by S. aureus observed upon SAL exposure may
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be caused mainly by high expression of saeRS and reduced
expression of mgrA. The relevance of our findings is underscored by the fact that aspirin, a main source of salicylic acid in
the human host, is being taken by millions of human beings
worldwide without medical prescription and is widely prescribed for defined purposes, including prevention of cardiac
infarction (58). Therefore, modulation of the invasive capacity
of bacteria may play a role in pathogenesis, prophylaxis, and
treatment of staphylococcal infections in certain at-risk populations colonized with S. aureus. It should not be forgotten,
however, that nonencapsulated S. aureus strains have a greater
ability to invade epithelial cells and may persist for long periods inside the host. Furthermore, persistent or recurrent infection may be favored by SAL administration.
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